Viloxazine Hydrochloride Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 100 mg, 150 mg, 200 mg
Reference Brands: Qelbree (USA)
Category:
Neurology
viloxazine hydrochloride is available in Capsules
and strengths such as 100 mg, 150 mg, 200 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, viloxazine hydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
viloxazine hydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Viloxazine is a centrally acting selective norepinephrine reuptake inhibitor that is marketed under the brand name Qelbree, among others, for the treatment of attention deficit hyperactivity disorder (ADHD) in both children and adults. ADHD is a neurodevelopmental condition characterized by inattention, hyperactivity, and impulsivity, which can significantly impact academic performance, work productivity, and social functioning.
Viloxazine has a long clinical history and was originally marketed for nearly three decades as an antidepressant for the treatment of depressive disorders before its discontinuation for that indication. Based on its mechanism of action and effects on norepinephrine signaling in the brain, it was later repurposed and developed for the management of ADHD. In its current approved use, viloxazine is administered orally as an extended-release formulation, allowing for sustained drug release and once-daily dosing.
The extended-release form is designed to provide steady symptom control throughout the day while offering a non-stimulant alternative for patients who may not tolerate or respond well to stimulant medications. Although clinical evidence suggests that viloxazine may be less effective in reducing ADHD symptoms compared to stimulant therapies such as methylphenidate, it remains a valuable treatment option for selected patients seeking non-stimulant management of ADHD.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing